1119451-22-7 Usage
Chemical structure
A complex organic compound with a piperidine core and a carboxylic acid functional group.
Functional groups
Contains a carboxylic acid functional group, which can form hydrogen bonds and participate in various chemical reactions.
Substituents
Has a 4-methylphenyl group and a 1,3-oxazol-4-yl group, both of which are connected to the piperidine core.
Methyl groups
The presence of two methyl groups (one on the 4-methylphenyl group and one on the 5-methyl-2-(4-methylphenyl)-1,3-oxazol-4-yl group) adds steric hindrance and can influence the compound's reactivity and physical properties.
Potential applications
Due to its complex structure and the presence of multiple functional groups, this chemical may have potential biological or pharmacological activity.
Further research
Additional research and testing would be needed to determine the specific properties, potential applications, and any possible side effects or toxicity of this compound.
Synthesis
The synthesis of this compound is not described in the material provided, but it likely involves multiple steps and the formation of various intermediates.
Purity
The purity of the synthesized compound is not mentioned, but it is an important factor to consider when evaluating its potential applications and properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1119451-22-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,9,4,5 and 1 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1119451-22:
(9*1)+(8*1)+(7*1)+(6*9)+(5*4)+(4*5)+(3*1)+(2*2)+(1*2)=127
127 % 10 = 7
So 1119451-22-7 is a valid CAS Registry Number.
1119451-22-7Relevant articles and documents
Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle
He, Shanshan,Li, Kelin,Lin, Billy,Hu, Zongyi,Xiao, Jingbo,Hu, Xin,Wang, Amy Q.,Xu, Xin,Ferrer, Marc,Southall, Noel,Zheng, Wei,Aubé, Jeffrey,Schoenen, Frank J.,Marugan, Juan J.,Liang, T. Jake,Frankowski, Kevin J.
, p. 6364 - 6383 (2017/08/02)
Reliance on hepatitis C virus (HCV) replicon systems and protein-based screening assays has led to treatments that target HCV viral replication proteins. The model does not encompass other viral replication cycle steps such as entry, processing, assembly and secretion, or viral host factors. We previously applied a phenotypic high-throughput screening platform based on an infectious HCV system and discovered an aryloxazole-based anti-HCV hit. Structure-activity relationship studies revealed several compounds exhibiting EC50 values below 100 nM. Lead compounds showed inhibition of the HCV pseudoparticle entry, suggesting a different mode of action from existing HCV drugs. Hit 7a and lead 7ii both showed synergistic effects in combination with existing HCV drugs. In vivo pharmacokinetics studies of 7ii showed high liver distribution and long half-life without obvious hepatotoxicity. The lead compounds are promising as preclinical candidates for the treatment of HCV infection and as molecular probes to study HCV pathogenesis.
